The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.

@article{Terpos2009TheUO,
  title={The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.},
  author={Evaggelos Terpos and Orhan Sezer and Peter Ian Croucher and Ram{\'o}n Garc{\'i}a-Sanz and Mario Boccadoro and Jes{\'u}s-F San Miguel and John Ashcroft and Juan Blade and Michele Cavo and Marc Delforge and M A Dimopoulos and Thierry Facon and Margaret Macro and Anders Waage and Peter Sonneveld},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2009},
  volume={20 8},
  pages={1303-17}
}
BACKGROUND Bisphosphonates (BPs) prevent, reduce, and delay multiple myeloma (MM)-related skeletal complications. Intravenous pamidronate and zoledronic acid, and oral clodronate are used for the management of MM bone disease. The purpose of this paper is to review the current evidence for the use of BPs in MM and provide European Union-specific recommendations to support the clinical practice of treating myeloma bone disease. DESIGN AND METHODS An interdisciplinary, expert panel of… CONTINUE READING
83 Extracted Citations
186 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 83 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 186 references

Randomised study on prophylactic pamidronate 30 mg versus 90 mg in multiple myeloma

  • P Gimsing, K Carlson, P Fayers
  • Blood
  • 2007
Highly Influential
12 Excerpts

National Comprehensive Cancer Network (NCCN). Multiple myeloma guidelines

  • K Anderson, M Alsina, W Bensinger
  • J Natl Compr Canc Netw
  • 2007
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…